FDA OKs Life Spine’s VersaLift Expandable Interbodies

Life Spine has earned U.S. Food and Drug Administration (FDA) clearance for its VersaLift expandable interbody system, a Micro Invasive solution for TLIF and PLIF surgeries featuring a 6 mm starting height.

VersaLift was designed to support minimally invasive access and boasts one of the smallest starting heights available for a TLIF expandable interbody implant. It’s approved for 8, 10, and 12 mm widths with up to 15° of lordotic correction. Its low profile design is meant to facilitate insertion through constrained anatomy while minimizing tissue disruption and nerve retraction.

VersaLift features controlled in situ expansion engineered to maintain implant length throughout deployment while helping restore anatomic disc height and facilitate indirect neural decompression. Its streamlined instrumentation enables surgeons to efficiently achieve alignment and procedural objectives while supporting a simplified, intuitive workflow.

“VersaLift represents our continued focus on procedural innovation and minimally invasive spine surgery,” said Rich Mueller, Life Spine’s president and CEO. “By combining a 6mm starting height with controlled in-situ expansion, VersaLift provides surgeons with a versatile expandable technology designed to address challenging anatomy while supporting procedural efficiency.”

In April, the FDA granted expanded indications for the company’s ARx SAI (Sacral Alar Iliac) Spinal Fixation System. ARx SAI is now approved for use with compatible pedicle screws with 5.5mm or 6mm posterior rods made from either titanium alloys or cobalt chrome, including those from competitor systems.